Methods: We performed an online survey within the International Paediatric Multiple Sclerosis Study Group between July and September 2020. The survey was sent to 130 members from 25 countries and consisted of five sections: demographic data, treatment, disease modifying therapies and COVID-19, outcome and three patient cases.
Results: The survey was completed by 66 members (51%), both paediatric neurologists and adult neurologists. Fingolimod and β-interferons were the most frequently used disease-modifying therapies, especially among paediatric neurologists. Almost a third (31%) of respondents had altered their prescribing practice due to COVID-19, in particular at the beginning of the pandemic.
Conclusions: The survey results indicate a tendency of moving from the traditional escalation therapy starting with injectables towards an early start with newer, highly effective disease modifying therapies. The COVID-19 pandemic only slightly affected prescribing patterns and treatment choices in paediatric MS.
|Journal||Multiple Sclerosis and Related Disorders|
|Early online date||27 Sep 2021|
|Publication status||Published - Nov 2021|
Bibliographical note© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
Funding: Financial support without any role in the design and conduct of this study was obtained from Stockholm City Council, Stiftelsen Barnforskningen vid Astrid Lindgrens Barnsjukhus and Sällskapet Barnavård.
- pediatric disease
- modifying therapy